Market News & Trends
Flexion Therapeutics & Xenon Pharmaceuticals Announce Acquisition
Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. recently announced the companies have entered into a definitive agreement that provides Flexion with the global rights to…
Novartis Investigational Lung Cancer Therapy Granted FDA Breakthrough Therapy Designation
"We are pleased to announce that the US FDA granted Breakthrough Therapy Designation to capmatinib (INC280) as a first-line treatment for patients with metastatic MET…
Nabriva Therapeutics Earns $5-Million Milestone Payment
Nabriva Therapeutics plc recently announced that Nabriva has earned a $5-million milestone payment under its licensing agreement with Sinovant Sciences related to the U.S. regulatory…
Catalent to Open New Clinical Supply Facility in San Diego
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, recently announced it…
Fate Therapeutics Announces FDA Clearance of IND Application
Fate Therapeutics, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for FT596, the company’s first off-the-shelf chimeric antigen…
Krystal Biotech Announces Initiation of Phase 1/2 Study
Krystal Biotech Inc. recently announced the initiation of the Phase 1/2 study of KB105 in transglutaminase-1 (TGM1) deficient autosomal recessive congenital ichthyosis (ARCI). The study, termed…
Atossa Genetics Announces Completion of Enrollment & Dosing in Phase 1 Clinical Trial
Atossa Genetics Inc. recently announced that all participant activities have been completed in its Phase 1 clinical trial of a new proprietary modified-release oral tablet form…
Innovent & Lilly Set to Transform Diabetes Medication as Clinical Trials Begin
Innovent Biologics, Inc. recently signed a licensing agreement with Eli Lilly and Company (Lilly), one of America’s leading pharmaceutical companies, for the development and potential…
Apellis Dosed First Patient in Phase 3 Study
Apellis Pharmaceuticals Inc.recently announced the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2…
Passage Bio Closes $110-Million Series B Financing
Passage Bio recently announced the closing of a $110-million Series B financing. The financing round was led by Access Biotechnology with participation from existing investors,…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….